All Relevant Subgroups With ESR1-Mutant MBC Derive PFS Benefit With Elacestrant
All Relevant Subgroups With ESR1-Mutant MBC Derive PFS Benefit With Elacestrant
https://www.oncnursingnews.com/view/...th-elacestrant "...In patients with HER2-low expression, median PFS was 9.03 months vs 1.87 months, respectively (HR, 0.301; 95% CI, 0.142-0.604)..." |
All times are GMT -7. The time now is 07:00 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021